Keith A. Katkin
Independent DirectorMr. Keith A. Katkin is Co-Founder and Chairman of Ambros Therapeutics, Inc. Mr. Katkin serves as Independent Director at Emergent BioSolutions Inc. April 01, 2022. He serves as Director at Transposon Therapeutics, Inc. He had been an Independent Director of Rigel Pharmaceuticals, Inc. since June 29, 2015 until May 19, 2022. Mr. Katkin served as Chief Executive Officer of Urovant Sciences Ltd. since May 2018 until March 23, 2020 and also had been its Director since July 2018 until March 23, 2020. He served as the Chief Executive Officer and President of Avanir Pharmaceuticals, Inc. from March 14, 2007 to January 20, 2016. Mr. Katkin served as Senior Vice President of Sales and Marketing of Avanir Pharmaceuticals from July 2005 to March 14, 2007 and has served as a Member of Avanir's Executive Management Team. Mr. Katkin served as Vice President of Commercial Development for Peninsula Pharmaceuticals Inc., from May 2004 to 2005 where he was responsible for all aspects of commercial development, including new product planning, business development and preparing for the possible launch of Peninsula's lead product candidate, Doripenem for injection. Mr. Katkin was responsible for creating and executing the plan that led to the approval of Nuedexta, the growth to commercial success and the recent acquisition of Rigel Pharmaceuticals, Inc. by Otsuka Pharmaceutical Co. in January 2015. He played a key role in the sale of Peninsula to Johnson & Johnson. He served as a Vice President of Pulmonary and Infectious Disease Marketing at InterMune Inc. from May 2002 to April 2004. He had been at Amgen in a variety of Sales and Marketing positions from 1996 to 2002. Mr. Katkin has experience within the pharmaceutical and biotechnology industry including marketing, national account sales, finance and business development. He has product launch and brand management experience on products such as Neupogen, Neulasta and Biaxin. Mr. Katkin's broad commercial experience at Amgen included brand management, national account sales and marketing, market research, channel distribution and pricing and contrActing. He directed hospital launch activities for Amgen's flagship anemia product, Aranesp. He had been at Abbott Laboratories in Finance, Business Development and Marketing roles. He is a highly accomplished biopharmaceutical executive with directly relevant experience having led the recent successful transition of Avanir into a fast growing, fully integrated biotech company with a market leading product. He has been the Independent Chairman of Eledon Pharmaceuticals, Inc. (formerly known as Novus Therapeutics, Inc.) (formerly Otic Pharma Ltd.) since May 2017 and serves as its Independent Director. He served as a Director at MC10, Inc. since November 15, 2016. He has been Director at Syndax Pharmaceuticals, Inc. since March 2017. He served as a Director of Carbylan Therapeutics, Inc. since December 4, 2014. He served as a Director of KalVista Pharmaceuticals, Inc. until September 2016. He served as a Director at Avanir Pharmaceuticals, Inc. from March 14, 2007 to January 13, 2015. He serves as a Board Member of CoverMyMeds and the Brain Injury Association of America. He is a licensed Certified Public Accountant in 1995. Mr. Katkin received a BS in Business and Accounting from Indiana University and an MBA in Finance with honors from the Anderson School of Management at the University of California, Los Angeles.
Positions
- Company NameSyndax Pharmaceuticals, Inc.Stock CodeSNDXPositionIndependent DirectorColleagues
- MAMichael A. MetzgerCEO & Director
- DGDennis G. PodlesakIndependent Chairman
- LJLuke J. AlbrechtGeneral Counsel & Corporate Secretary
- KAKeith Alan GoldanExecutive Officer
- SCSteven ClosterChief Commercial Officer
- NANicholas A.J. BotwoodHead of Research & Development and Chief Medical Officer
- PLPierre LegaultIndependent Director
- JAJennifer A. JarrettIndependent Director
- Company NameEledon Pharmaceuticals, Inc.Stock CodeELDNPositionIndependent Chairman of the BoardColleagues
- DCDavid-Alexandre C. GrosCEO & Non Independent Director
- KAKeith A. KatkinIndependent Chairman of the Board
- SNSteven N. PerrinPresident, Chief Scientific Officer & Non Independent Director
- PSPaul Sean LittleChief Financial Officer
- JHJohn HerbergerVice President of Technical Operations
- BEBryan E. SmithGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- JSJohn S. McBrideIndependent Director
- JAJames A. RobinsonIndependent Director
